HMG CoA reductase inhibitor fluvastatin arrests the development of implanted hepatocarcinoma in rats.
BACKGROUND
Fluvastain (Flu) is widely accepted to have anticancer effect although its in vivo chemopreventive ability in cancer has not been studied. The therapeutic and chemopreventive effects of Flu were compared in vivo in the present study.


METHODS
Under the left renal capsule of FLF1 hybrid rats 10(6) hepatocarcinoma cells were implanted (He/De14) on sponge disc. The differences in net weight between the left and right kidneys were determined as tumor weights. Flu was administered per os in 0.5, 2 and 20 mg/kg/day doses.


RESULTS
The 21-day pretreatment before tumor implantation with Flu had no effect on tumor development in the absence of Flu treatment after the implantation. The addition of Flu before and after tumor implantation demonstrated a more intensive anticancer effect than in the case of treatment given only after tumor implantation.


CONCLUSIONS
Flu has in 0.5-20 mg/kg/day doses a therapeutic and also a preventive effect on hepatocarcinoma growth in rats depending on the type of administration.
Paragh
György
G
First Department of Medicine, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary, H-4012. paragh@ibel.dote.hu
Kertai
Pal
P
Kovacs
Péter
P
Paragh
György
G
Fülöp
Péter
P
Foris
Gabriella
G
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D005229:Fatty Acids, Monounsaturated / Q000494:pharmacology*; D000077340:Fluvastatin; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology*; D007211:Indoles / Q000494:pharmacology*; D008114:Liver Neoplasms, Experimental / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D008297:Male; D051381:Rats; D011916:Rats, Inbred F344
D000970:Antineoplastic Agents; D005229:Fatty Acids, Monounsaturated; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007211:Indoles; D000077340:Fluvastatin